Guggenheim Reaffirms “Buy” Rating for InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reissued by investment analysts at Guggenheim in a research note issued on Tuesday,Benzinga reports. They presently have a $14.00 price target on the stock.

Other research analysts have also issued reports about the stock. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of InflaRx in a report on Tuesday, December 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research report on Friday, March 27th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.17.

InflaRx Stock Up 1.0%

NASDAQ:IFRX opened at $1.68 on Tuesday. InflaRx has a 52-week low of $0.71 and a 52-week high of $1.94. The stock has a fifty day simple moving average of $0.96 and a 200-day simple moving average of $1.09. The company has a market capitalization of $121.16 million, a PE ratio of -2.20 and a beta of 1.49.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Friday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.17). The business had revenue of ($0.04) million for the quarter, compared to analyst estimates of $0.03 million. As a group, equities analysts anticipate that InflaRx will post -0.6 earnings per share for the current year.

Institutional Trading of InflaRx

Large investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in InflaRx in the 4th quarter worth approximately $135,000. Suvretta Capital Management LLC lifted its holdings in shares of InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after buying an additional 1,450,000 shares during the period. Quadrature Capital Ltd bought a new stake in InflaRx in the fourth quarter worth about $104,000. Eversept Partners LP lifted its holdings in InflaRx by 1.5% in the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock valued at $1,775,000 after acquiring an additional 26,677 shares during the last quarter. Finally, 683 Capital Management LLC boosted its position in shares of InflaRx by 47.3% during the 4th quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after purchasing an additional 1,065,000 shares in the last quarter. Institutional investors and hedge funds own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.